Trial · NCT06225752
Probucol for Symptomatic Intracranial and Extracranial Artery Stenosis
NCT06225752, Phase 3, Recruiting, First Affiliated Hospital of Wannan Medical College
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Probucol for Symptomatic Intracranial and Extracranial Artery Stenosis. Trials, record NCT06225752. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06225752
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Probucol for Symptomatic Intracranial and Extracranial Artery Stenosis
- NCT number
- NCT06225752
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 5,452 participants, estimated
- Lead sponsor
- First Affiliated Hospital of Wannan Medical College
- Conditions
- Ischemic Stroke, TIA
- Interventions
- Probucol, Placebo probucol
- First posted
- 2024-01-26
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recurrent stroke event | within 1 year | Ischemic or hemorrhagic stroke |
| Secondary | Recurrent ischemic stroke event | within 1 year | Incidence of any new ischemic stroke |
| Secondary | Composite vascular events | within 1 year | Including ischemic stroke, hemorrhagic stroke, myocardial infarction and vascular death |
| Secondary | Poor functional outcome | within 1 year | Defined as a modified Rankin Scale (mRS) score ≥3(The mRS Scale is used to evaluate the recovery of neurological function in stroke patients. It consists of a seven-point scale, with Grade 0 indicating no symptoms at all. Grade 1 represents the presence of symptoms but without significant disability, allowing for the performance of regular jobs and activities. Grade 2 signifies mild disability where individuals are unable to perform all work and activities but can manage personal affairs independently. Grade 3 indicates moderate disability requiring assistance from others for walking without aid. Grade 4 denotes severe disability where individuals cannot walk unassisted and are unable to care for their own needs. Grade 5 represents severe disability with bedridden status, incontinence, and necessitating continuous care round-the-clock. Finally, Grade 6 signifies death.) |
| Secondary | All-cause mortality | within 1 year | Death from any cause |
| Other | Change in levels of oxidized low-density lipoprotein cholesterol (Ox-LDL) | within 1 year | Ox-LDL is a component specific to the atherosclerotic lesion area that is not present in normal arterial vascular tissue and is elevated in atherosclerotic strokes |
| Other | Change in the rate of responsible vessel stenosis | within 1 year | Stenosis of the responsible vessel at enrollment \>50% |
| Other | Adverse events | within 1 year | The difference in the proportion of adverse events (AEs) between Probucol and the placebo group |
| Other | Severe adverse events | within 1 year | The difference in the proportion of serious adverse events (SAEs) between Probucol and the placebo group; |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06225752
GET https://conductscience.org/api/trials/v1/NCT06225752/registered